ciprofloxacin has been researched along with Infection in 30 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized, double-blind, multicenter trial, ciprofloxacin/metronidazole was compared with imipenem/cilastatin for treatment of complicated intra-abdominal infections." | 9.08 | Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. ( Bjornson, HS; Bohnen, JM; Coulter, HO; Dellinger, EP; Echols, RM; Haverstock, DC; Hill, CS; Reinhart, HH; Rotstein, OD; Simms, HH; Solomkin, JS; Vogel, SB, 1996) |
| "New fluoroquinolones, as exemplified by levofloxacin, possess broad spectrum activity against many common pathogens, including the majority responsible for respiratory tract infections (RTIs), atypical pathogens and those resistant to other therapeutic regimens." | 8.82 | Clinical applications of levofloxacin for severe infections. ( Graninger, W; Zeitlinger, M, 2004) |
| "To evaluate different concentrations of ciprofloxacin to prevent infection after open fracture contaminated with S." | 7.96 | Prevention of bone infection after open fracture using a chitosan with ciprofloxacin implant in animal model. ( Araújo, ID; Faraco, AAG; Fernandes, SOA; Kobata, SI; Teixeira, LEM; Vidigal, PVT, 2020) |
| "A 23-year old male with a history of schizophrenia treated with clozapine 900 mg/d was admitted to the hospital for a gastrointestinal infection." | 7.78 | A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. ( Espnes, KA; Heimdal, KO; Spigset, O, 2012) |
| "To analyze the efficacy of Ciprodex otic augmented with N-acetylcysteine (NAC) against difficult ear infections." | 7.74 | N-Acetylcysteine as an adjunct for refractory ear infections. ( Choe, WT; Murray, MT; Roberson, JB; Stidham, KR, 2007) |
| "In a randomized study comparing cotrimoxazole plus colistin with ciprofloxacin, each in combination with nonabsorbable antimycotics, the incidence of major infections in terms of septicemias and pneumonias as well as of minor infections and episodes of unexplained fever (FUO) was higher in patients treated with ciprofloxacin." | 6.16 | Prevention of infection in acute leukemia. ( Daenen, S; de Pauw, BE; de Vries-Hospers, HG; Dekker, AW; Donnelly, JP; Gaus, W; Haralambie, E; Kern, W; Konrad, H; Maschmeyer, G, 1990) |
| "Biodistribution results in induced infection mice showed (99m)Tc(CO)(3)-CPFXDTC had higher uptake at the sites of infection and better abscess/blood and abscess/muscle ratios than those of (99m)Tc-ciprofloxacin and (99m)TcN-CPFXDTC." | 5.36 | Synthesis and biological evaluation of a novel 99mTc(CO)3 complex of ciprofloxacin dithiocarbamate as a potential agent to target infection. ( Guo, H; Wang, X; Zhang, J; Zhang, S, 2010) |
| "In a randomized, double-blind, multicenter trial, ciprofloxacin/metronidazole was compared with imipenem/cilastatin for treatment of complicated intra-abdominal infections." | 5.08 | Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. ( Bjornson, HS; Bohnen, JM; Coulter, HO; Dellinger, EP; Echols, RM; Haverstock, DC; Hill, CS; Reinhart, HH; Rotstein, OD; Simms, HH; Solomkin, JS; Vogel, SB, 1996) |
| "A multicenter, prospective, randomized study was performed to compare the cost-effectiveness of parenteral antibiotic versus parenteral antibiotic + oral ciprofloxacin sequential therapy in the treatment of moderate and severe infections in hospitalized patients." | 5.08 | [Study of the cost-effectiveness of sequential antibiotic (ciprofloxacin) therapy]. ( Kovács, G; Ludwig, E; Nagy, G; Székely, E, 1997) |
| "Ciprofloxacin and gentamicin, each in combination with metronidazole, were equivalent in their ability to prevent infections after penetrating abdominal trauma; other factors, especially the receipt of blood transfusions, had much more effect on the incidence of infection." | 5.08 | A trial of ciprofloxacin and metronidazole vs gentamicin and metronidazole for penetrating abdominal trauma. ( McCreadie, S; Tyburski, JG; Warsow, KM; Wilson, RF, 1998) |
| "Eighty-six men with uncomplicated gonorrhoea were entered into a study comparing the efficacy of a single oral dose of 250 mg of ciprofloxacin with a single oral dose of ampicillin 2 g and probenecid 1 g for urethral gonorrhoea and a course of ampicillin, 500 mg four times per day for five days in rectal and pharyngeal infection." | 5.06 | Ciprofloxacin versus ampicillin and probenecid in the treatment of uncomplicated gonorrhoea in men. ( McMillan, A; Scott, GR; Young, H, 1987) |
| " The duration of treatment for uncomplicated pyelonephritis can be safely shortened to 7 days when using ciprofloxacin." | 4.89 | [Infectious diseases]. ( Malinverni, R; Pittet, R, 2013) |
| "DRAXIMAGE, under exclusive licence from BTG International Ltd, is developing a technetium-99m formulation of ciprofloxacin (INFECTON), as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis." | 4.82 | 99mTc-ciprofloxacin DRAXIMAGE. ( Tossing, G, 2004) |
| "New fluoroquinolones, as exemplified by levofloxacin, possess broad spectrum activity against many common pathogens, including the majority responsible for respiratory tract infections (RTIs), atypical pathogens and those resistant to other therapeutic regimens." | 4.82 | Clinical applications of levofloxacin for severe infections. ( Graninger, W; Zeitlinger, M, 2004) |
| "To evaluate different concentrations of ciprofloxacin to prevent infection after open fracture contaminated with S." | 3.96 | Prevention of bone infection after open fracture using a chitosan with ciprofloxacin implant in animal model. ( Araújo, ID; Faraco, AAG; Fernandes, SOA; Kobata, SI; Teixeira, LEM; Vidigal, PVT, 2020) |
| "A 23-year old male with a history of schizophrenia treated with clozapine 900 mg/d was admitted to the hospital for a gastrointestinal infection." | 3.78 | A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. ( Espnes, KA; Heimdal, KO; Spigset, O, 2012) |
| "To analyze the efficacy of Ciprodex otic augmented with N-acetylcysteine (NAC) against difficult ear infections." | 3.74 | N-Acetylcysteine as an adjunct for refractory ear infections. ( Choe, WT; Murray, MT; Roberson, JB; Stidham, KR, 2007) |
| " In experimental models of localized or disseminated bacterial and fungal infections, the sterically stabilized liposomes have successfully been used to improve antibiotic treatment using representative agents of various classes of antibacterial agents such as the beta-lactams, the aminoglycosides, and the quinolones or the antifungal agent amphotericin B." | 3.73 | Long-circulating sterically stabilized liposomes in the treatment of infections. ( Bakker-Woudenberg, IA; Becker, MJ; Guo, L; Schiffelers, RM; Storm, G, 2005) |
| "This study was designed to retrospectively review the experience in this center with oral ciprofloxacin 500 mg bid and ip vancomycin 25 mg/L in the treatment of CAPD-related exit site infections and to determine the relationship between exit site infections and peritonitis." | 3.68 | Relationship between peritonitis and exit site infections in CAPD. ( Bailie, GR; Eisele, G; Lomaestro, B, 1992) |
| "There is a clear knowledge gap regarding the bioavailability of orally administered antibiotics in non-ICU patients during the initial phase of a systemic infection." | 2.72 | Systematic review: the bioavailability of orally administered antibiotics during the initial phase of a systemic infection in non-ICU patients. ( Prins, JM; van den Broek, AK; van Hest, RM; Visser, CE, 2021) |
| "Biodistribution results in induced infection mice showed (99m)Tc(CO)(3)-CPFXDTC had higher uptake at the sites of infection and better abscess/blood and abscess/muscle ratios than those of (99m)Tc-ciprofloxacin and (99m)TcN-CPFXDTC." | 1.36 | Synthesis and biological evaluation of a novel 99mTc(CO)3 complex of ciprofloxacin dithiocarbamate as a potential agent to target infection. ( Guo, H; Wang, X; Zhang, J; Zhang, S, 2010) |
| "Bacterial wound infection is a major problem, which hinders the normal healing process." | 1.34 | Collagen bilayer dressing with ciprofloxacin, an effective system for infected wound healing. ( Ahmed, MR; Kumar, MS; Sehgal, PK; Sripriya, R, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 8 (26.67) | 18.2507 |
| 2000's | 10 (33.33) | 29.6817 |
| 2010's | 8 (26.67) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chrysouli, MP | 1 |
| Banti, CN | 1 |
| Kourkoumelis, N | 1 |
| Moushi, EE | 1 |
| Tasiopoulos, AJ | 1 |
| Douvalis, A | 1 |
| Papachristodoulou, C | 1 |
| Hatzidimitriou, AG | 1 |
| Bakas, T | 1 |
| Hadjikakou, SK | 1 |
| Kobata, SI | 1 |
| Teixeira, LEM | 1 |
| Fernandes, SOA | 1 |
| Faraco, AAG | 1 |
| Vidigal, PVT | 1 |
| Araújo, ID | 1 |
| van den Broek, AK | 1 |
| Prins, JM | 1 |
| Visser, CE | 1 |
| van Hest, RM | 1 |
| Hasanzadeh, A | 1 |
| Pourmand, MR | 1 |
| Alizadeh, A | 1 |
| Pourmand, G | 1 |
| Hornyák, I | 1 |
| Madácsi, E | 1 |
| Kalugyer, P | 1 |
| Vácz, G | 1 |
| Horváthy, DB | 1 |
| Szendrői, M | 1 |
| Han, W | 1 |
| Lacza, Z | 1 |
| Zhang, J | 1 |
| Zhang, S | 1 |
| Guo, H | 1 |
| Wang, X | 1 |
| Jayathissa, S | 1 |
| Woolley, M | 1 |
| Ganasegaram, M | 1 |
| Holden, J | 1 |
| Cu, E | 1 |
| Eleutherakis-Papaiakovou, E | 1 |
| Kostis, E | 1 |
| Migkou, M | 1 |
| Christoulas, D | 1 |
| Terpos, E | 1 |
| Gavriatopoulou, M | 1 |
| Roussou, M | 1 |
| Bournakis, E | 1 |
| Kastritis, E | 1 |
| Efstathiou, E | 1 |
| Dimopoulos, MA | 1 |
| Papadimitriou, CA | 1 |
| Utrera, NM | 1 |
| Álvarez, MB | 1 |
| Polo, JM | 1 |
| Sánchez, AT | 1 |
| Martínez, JP | 1 |
| González, RD | 1 |
| Espnes, KA | 1 |
| Heimdal, KO | 1 |
| Spigset, O | 1 |
| Pittet, R | 1 |
| Malinverni, R | 1 |
| Kästenbauer, T | 1 |
| Hörnlein, B | 1 |
| Sokol, G | 1 |
| Irsigler, K | 1 |
| Choe, W | 1 |
| Kan Ryu, J | 1 |
| Kim, WH | 1 |
| Chung, MH | 1 |
| Suh, JK | 1 |
| Tossing, G | 1 |
| Graninger, W | 1 |
| Zeitlinger, M | 1 |
| Weyenberg, W | 1 |
| Vermeire, A | 1 |
| Dhondt, MM | 1 |
| Adriaens, E | 1 |
| Kestelyn, P | 1 |
| Remon, JP | 1 |
| Ludwig, A | 1 |
| Veiranto, M | 1 |
| Suokas, E | 1 |
| Ashammakhi, N | 1 |
| Törmälä, P | 2 |
| Bakker-Woudenberg, IA | 1 |
| Schiffelers, RM | 1 |
| Storm, G | 1 |
| Becker, MJ | 1 |
| Guo, L | 1 |
| Sripriya, R | 1 |
| Kumar, MS | 1 |
| Ahmed, MR | 1 |
| Sehgal, PK | 1 |
| Choe, WT | 1 |
| Murray, MT | 1 |
| Stidham, KR | 1 |
| Roberson, JB | 1 |
| Solomkin, JS | 1 |
| Reinhart, HH | 1 |
| Dellinger, EP | 1 |
| Bohnen, JM | 1 |
| Rotstein, OD | 1 |
| Vogel, SB | 1 |
| Simms, HH | 1 |
| Hill, CS | 1 |
| Bjornson, HS | 1 |
| Haverstock, DC | 1 |
| Coulter, HO | 1 |
| Echols, RM | 1 |
| Ludwig, E | 1 |
| Kovács, G | 1 |
| Nagy, G | 1 |
| Székely, E | 1 |
| Tyburski, JG | 1 |
| Wilson, RF | 1 |
| Warsow, KM | 1 |
| McCreadie, S | 1 |
| Barriere, SL | 1 |
| Lang, SD | 1 |
| Bassetti, M | 1 |
| Melica, G | 1 |
| Di Biagio, A | 1 |
| Bassetti, D | 1 |
| Eisele, G | 1 |
| Bailie, GR | 1 |
| Lomaestro, B | 1 |
| Teupe, C | 1 |
| Meffert, R | 1 |
| Winckler, S | 1 |
| Ritzerfeld, W | 1 |
| Brug, E | 1 |
| Maschmeyer, G | 1 |
| Daenen, S | 1 |
| de Pauw, BE | 1 |
| de Vries-Hospers, HG | 1 |
| Dekker, AW | 1 |
| Donnelly, JP | 1 |
| Gaus, W | 1 |
| Haralambie, E | 1 |
| Kern, W | 1 |
| Konrad, H | 1 |
| Scott, GR | 1 |
| McMillan, A | 1 |
| Young, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media[NCT00956748] | Phase 4 | 0 participants (Actual) | Interventional | 2019-11-29 | Withdrawn (stopped due to Lack of staff, time, and resources) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ciprofloxacin and Infection
| Article | Year |
|---|---|
Systematic review: the bioavailability of orally administered antibiotics during the initial phase of a systemic infection in non-ICU patients.
Topics: Administration, Oral; Anti-Bacterial Agents; Biological Availability; Ciprofloxacin; Fever; Humans; | 2021 |
[Infectious diseases].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Diabetic Foot; Endocarditis; Humans; Infections; Plant Extract | 2013 |
99mTc-ciprofloxacin DRAXIMAGE.
Topics: Animals; Ciprofloxacin; Clinical Trials as Topic; Drugs, Investigational; Humans; Infections; Organo | 2004 |
Clinical applications of levofloxacin for severe infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; | 2004 |
Prevention of infection in acute leukemia.
Topics: Acute Disease; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Therapy, Combination; Humans; In | 1990 |
8 trials available for ciprofloxacin and Infection
| Article | Year |
|---|---|
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Fever; Graft Survival; Hematologic Neo | 2010 |
Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Bed Rest; Cellulitis; Ciprofloxacin; Clindamycin | 2003 |
Ocular bioerodible minitablets as strategy for the management of microbial keratitis.
Topics: Absorbable Implants; Administration, Topical; Adult; Anti-Infective Agents; Chromatography, High Pre | 2004 |
Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.
Topics: Abdomen; Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Cilastatin; Cilastati | 1996 |
[Study of the cost-effectiveness of sequential antibiotic (ciprofloxacin) therapy].
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cost-Benefit Analysis; Female; Humans; Hungary; Infecti | 1997 |
A trial of ciprofloxacin and metronidazole vs gentamicin and metronidazole for penetrating abdominal trauma.
Topics: Abdominal Injuries; Adult; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Drug Therapy, | 1998 |
Prevention of infection in acute leukemia.
Topics: Acute Disease; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Therapy, Combination; Humans; In | 1990 |
Ciprofloxacin versus ampicillin and probenecid in the treatment of uncomplicated gonorrhoea in men.
Topics: Ampicillin; Ciprofloxacin; Gonorrhea; Humans; Infections; Male; Microbial Sensitivity Tests; Pharyng | 1987 |
18 other studies available for ciprofloxacin and Infection
| Article | Year |
|---|---|
Ciprofloxacin conjugated to diphenyltin(IV): a novel formulation with enhanced antimicrobial activity.
Topics: Anti-Infective Agents; Biofilms; Ciprofloxacin; Drug Compounding; Drug Liberation; Humans; Infection | 2020 |
Prevention of bone infection after open fracture using a chitosan with ciprofloxacin implant in animal model.
Topics: Animals; Bony Callus; Chitosan; Ciprofloxacin; Femoral Fractures; Fracture Healing; Fractures, Open; | 2020 |
Prevalence and significance of fluoroquinolone-resistant bacteria carriage in patients undergoing transrectal ultrasound prostate biopsy.
Topics: Aged; Anti-Bacterial Agents; Carrier State; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia c | 2017 |
Increased release time of antibiotics from bone allografts through a novel biodegradable coating.
Topics: Allografts; Amoxicillin; Biocompatible Materials; Bone Transplantation; Chitosan; Ciprofloxacin; Hum | 2014 |
Synthesis and biological evaluation of a novel 99mTc(CO)3 complex of ciprofloxacin dithiocarbamate as a potential agent to target infection.
Topics: Animals; Bacterial Adhesion; Blood; Ciprofloxacin; Drug Stability; Infections; Mice; Muscle, Skeleta | 2010 |
Myoclonus and delirium associated with ciprofloxacin.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Delirium; Hip Joint; Humans; Infections; Male; Myoclonus | 2010 |
Infectious complications after transrectal ultrasound-guided prostatic biopsy. Analysis of our experience.
Topics: Aged; Anti-Bacterial Agents; Bacteriuria; Biopsy, Fine-Needle; Ciprofloxacin; Humans; Infections; Ma | 2011 |
A puzzling case of increased serum clozapine levels in a patient with inflammation and infection.
Topics: Adult; Anti-Bacterial Agents; Antipsychotic Agents; Ciprofloxacin; Clozapine; Drug Interactions; Dru | 2012 |
Imaging seminal vesiculitis with Tc-99m ciprofloxacin.
Topics: Ciprofloxacin; Humans; Infections; Male; Middle Aged; Organotechnetium Compounds; Prostatitis; Radio | 2003 |
Novel bioabsorbable antibiotic releasing bone fracture fixation implants.
Topics: Anti-Infective Agents; Biocompatible Materials; Ciprofloxacin; Drug Delivery Systems; Fracture Fixat | 2004 |
Long-circulating sterically stabilized liposomes in the treatment of infections.
Topics: Ammonium Sulfate; Amphotericin B; Animals; Anti-Infective Agents; Ceftazidime; Ciprofloxacin; Drug C | 2005 |
Collagen bilayer dressing with ciprofloxacin, an effective system for infected wound healing.
Topics: Animals; Anti-Bacterial Agents; Cattle; Ciprofloxacin; Collagen; Disease Models, Animal; Infections; | 2007 |
N-Acetylcysteine as an adjunct for refractory ear infections.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Inflammatory Agents; Antiviral | 2007 |
Efficacy and cost-effectiveness of oral ciprofloxacin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cost-Benefit Analysis; Economics, Pharmaceutical; Humans; Infe | 1992 |
Oral ciprofloxacin versus intravenous antibiotics.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cost Savings; Humans; Infections; Infusi | 1992 |
Ciprofloxacin and ICU.
Topics: Anti-Infective Agents; Ciprofloxacin; Critical Care; Humans; Infections; Superinfection | 2002 |
Relationship between peritonitis and exit site infections in CAPD.
Topics: Ciprofloxacin; Humans; Infections; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Recurren | 1992 |
Ciprofloxacin-impregnated poly-L-lactic acid drug carrier. New aspects of a resorbable drug delivery system in local antimicrobial treatment of bone infections.
Topics: Biological Assay; Bone Diseases; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; | 1992 |